| Literature DB >> 32275786 |
Reid W Merryman1, Nicole A Carreau2, Ranjana H Advani3, Michael A Spinner3, Alex F Herrera4, Robert Chen4, Sarah Tomassetti4, Radhakrishnan Ramchandren5, Muhammad Hamid5, Sarit Assouline6, Raoul Santiago6, Nina Wagner-Johnston7, Suman Paul7, Jakub Svoboda8, Steven M Bair8, Stefan K Barta9, Yang Liu9, Sunita Nathan10, Reem Karmali11, Madelyn Burkart12, Pallawi Torka13, Kevin A David14, Catherine Wei14, Frederick Lansigan15, Lukas Emery15, Daniel Persky16, Sonali M Smith17, James Godfrey17, Julio Chavez18, Jonathan B Cohen19, Andrea B Troxel20, Catherine Diefenbach20, Philippe Armand1.
Abstract
Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treated with ICB; 20 who received TBP (TBP cohort) and 44 who stopped ICB at initial progression (non-TBP cohort). The TBP cohort received ICB for a median of 4.7 months after initial progression and delayed subsequent treatment by a median of 6.6 months. Despite receiving more prior lines of therapy, the TBP cohort achieved longer progression-free survival with post-ICB treatment (median, 17.5 months vs. 6.1 months, p = .035) and longer time-to-subsequent treatment failure, defined as time from initial ICB progression to failure of subsequent treatment (median, 34.6 months vs. 9.9 months, p = .003). With the limitations of a retrospective study, these results support the clinical benefit of TBP with ICB for selected patients. © AlphaMed Press 2020.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32275786 PMCID： PMC7288660 DOI： 10.1634/theoncologist.2020-0040
Source DB: PubMed Journal: Oncologist ISSN： 1083-7159